Results 21 to 30 of about 1,129 (187)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. [PDF]

Trials, 2015
Background Patient characteristics and blood pressure-related outcomes in randomized clinical trials (RCTs) differ from clinical practice because of stringent selection criteria.
Bramlage P, Schmieder RE, Gitt AK, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Potthoff SA, EARLY Registry Group.   +9 more
europepmc   +3 more sources

The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. [PDF]

J Clin Hypertens (Greenwich), 2011
The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory ...
Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S.   +7 more
europepmc   +4 more sources

Authors’ Reply: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study [PDF]

Epidemiology and Health
Hyesung Lee, Bin Hong, Chris Tzu-Ting Su, Sungho Bea, Han Eol Jeong, Kyungyeon Jung, Michael Chun-Yuan Cheng, Zoe Chi-Jui Chang, Edward Chia-Cheng Lai, Jongyoung Lee   +9 more
doaj   +2 more sources

Letter to the Editor: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study [PDF]

Epidemiology and Health
Zhanyi Zhou
doaj   +2 more sources

Azilsartan medoxomil [PDF]

, 2020
Azilsartan is used for treatment of the high blood pressure (hypertension). Reducing high blood pressure enables avoid strokes, heart attacks and problems of kidneys. Azilsartan comes under the name angiotensin receptor blocker (ARBs) as a class of drugs. It acts by relaxing blood vessels to make it easier for blood to flow.
Abdulrahman A, Al-Majed, Ahmed H H, Bakheit, Ali, Al-Muhsin, Hamad M, Al-Kahtani, Ali S, Abdelhameed   +4 more
openaire   +3 more sources

The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders

Терапевтический архив, 2021
Aim. To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders. Materials and methods.
Vera A. Nevzorova, Tatiana A. Petrichko, Irina E. Chazova, Juliya V. Zhernakova   +3 more
doaj   +1 more source

Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial

The Journal of Clinical Hypertension, Volume 25, Issue 9, Page 817-827, September 2023., 2023
Abstract The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double‐blind, active‐controlled, phase 3, randomized trial.
Eun Joo Cho, Moo Hyun Kim, Young‐Hak Kim, Kiyuk Chang, Dong‐Ju Choi, Woong Chol Kang, Jinho Shin, Seong Hwan Kim, Namho Lee, Jang Won Son, Joon‐Hyung Doh, Woo‐Shik Kim, Soon Jun Hong, Moo‐Yong Rhee, Youngkeun Ahn, Sang‐Wook Lim, Seung Pyo Hong, So‐Yeon Choi, Min Su Hyon, Jin‐Yong Hwang, Kihwan Kwon, Kwang Soo Cha, Sang‐Hyun Ihm, Jae‐Hwan Lee, Byung‐Su Yoo, Hyo‐Soo Kim   +25 more
wiley   +1 more source

Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions

British Journal of Clinical Pharmacology, Volume 88, Issue 11, Page 4812-4827, November 2022., 2022
Aims The aim of this study was to determine if any suspected adverse drug reactions (ADRs) observed with the use of angiotensin II receptor blockers (ARBs) could be linked to either (a) their unique respective physicochemical and pharmacological profiles and (b) the recently disclosed suspected carcinogenic manufacturing contaminants found in certain ...
Hamisha Salim, Alan M. Jones
wiley   +1 more source

CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride

Clinical and Translational Science, Volume 15, Issue 11, Page 2613-2624, November 2022., 2022
Abstract Cinitapride is a gastrointestinal prokinetic drug, prescribed for the treatment of functional dyspepsia, and as an adjuvant therapy for gastroesophageal reflux disease. In this study, we aimed to explore the impact of relevant variants in CYP3A4 and CYP2C8 and other pharmacogenes, along with demographic characteristics, on cinitapride ...
Diana María Campodónico, Pablo Zubiaur, Paula Soria‐Chacartegui, Ana Casajús, Gonzalo Villapalos‐García, Marcos Navares‐Gómez, Antía Gómez‐Fernández, Raúl Parra‐Garcés, Gina Mejía‐Abril, Manuel Román, Samuel Martín‐Vílchez, Dolores Ochoa, Francisco Abad‐Santos   +12 more
wiley   +1 more source

Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta‐analysis of randomized controlled trials

The Journal of Clinical Hypertension, Volume 24, Issue 8, Page 971-983, August 2022., 2022
Abstract Hypertension is a prevalent risk factor for cardiovascular disease. Angiotensin II receptor blockers are widely prescribed to patients with hypertension, while new drugs are continuously developed. However, data on comparative efficacy and safety of novel agents, such as fimasartan, are scarce.
Suk Min Seo, Sang Hyun Ihm, Jeong‐Eun Yi, Seung Hee Jeong, Bong‐Seog Kim   +4 more
wiley   +1 more source